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SAFETY OF DRUG TREATMENT IN PREGNANT 
PATIENTS WITH GERD?
“Heartburn” is a symptom that can be seen in 30%-50% 
pregnancies. It particularly develops at the end of the 
first trimester, in the second trimester, and it becomes 
more apparent in the last trimester (1-3). Basal lower 
esophageal sphincter (LES) pressure may not change in 
the first trimester. The reason for this is demonstrated 
to be the low response to physiological stimuli such 
as pentagastrin, edrophonium chloride, methacholine, 
and food with protein in the first trimester of pregnan-
cy. The LES pressure may decrease to 33%-50% of basal 
values in the second trimester. During the second and 
third trimesters, a decrease in the LES pressure can be 
observed due to the elevated intra-abdominal pressure, 
increased progesterone, abnormal gastric discharge, or 
delayed intestinal transit (4).
Antacids
In a previous retrospective case-controlled study on 
the use of antacids in pregnancy, no increase was de-
tected in the development of congenital anomaly with 
aluminum hydroxide, sodium bicarbonate, magnesium 
trisilicate, and calcium carbonate (5,6). Authors of this 
study reported that antacids having therapeutic doses 
of aluminum, magnesium, and calcium can be safely 
used during pregnancy (7).
In a European consensus meeting conducted in 2003 
(Contemporary understanding and management of 
reflux and constipation in the general population and 
pregnancy: a consensus meeting), it was reported that 
the use of calcium-based antacids in pregnant women 
with GERD could be beneficial because it reduced the 
risk of hypertension and preeclampsia (8). Moreover, 
in a comprehensive randomized placebo-controlled 
study, it was demonstrated that the use of magnesium 
sulfate during pregnancy reduced eclampsia and ma-
ternal risk; it also caused no serious side effects in the 
short term. Antacids having sodium bicarbonate must 
be avoided because they can lead to metabolic alkalo-
sis and increased fluid load both in the mother and the 
fetus (5).
Alginate builds a non-systemic strong barrier against acid 
and food reflux in the esophagus. In an open-labeled 
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multi-centered study including 150 cases, the use of alginate for 
over 4 weeks yielded satisfying results both for physician and for 
patient, but fetal distress was observed in 3 fetuses (9). In another 
multi-centered (South Africa and United Kingdom) prospective 
study, a total of 144 women were given alginate therapy at a 
maximum dose of 80 mL/day for 4 weeks during their pregnan-
cies. While side effects directly related to the drug, such as diar-
rhea and nausea, were observed only in 3 of the mothers using 
alginate, fetus-related perinatal morbidity and mortality rates 
were found to be similar to normal population incidences (10).
Sucralfate
Sucralfate is a sulfated disaccharide salt. It is absorbed from the 
gastrointestinal system at a minimal level and it exhibits a local 
mucosal protective effect. It inhibits the activity of pepsin and 
prevents the development of ulcers (5). The teratogenic effect 
of sucralfate has not been revealed, although it was used at a 
50-times higher dose in animal models than in human subjects 
(9). In an Italian study conducted on the safety of sucralfate use 
in pregnancy, 42 women were administered 3×1 g/day doses 
of sucralfate for a month: no maternal or fetal side effects were 
reported (11). In a surveillance study in which 229101 preg-
nancies were examined between 1985 and 1992, birth defects 
were observed only in 5 out of 185 newborns that were ex-
posed to sucralfate during the first trimester: this rate is below 
the expected rate of birth defects (5/185 vs. 8/185) (9).
Metoclopramide
Metoclopramide, which is a dopamine-2 receptor antagonist, 
prevents gastroesophageal reflux by increasing the LES pres-
sure. In addition, it is effective in the treatment of GERD be-
cause it increases the esophageal acid clearance and acceler-
ates gastric drainage.
Metoclopramide rapidly passes through the placenta and the 
plasma concentration of the fetus can reach 60%–70% of the 
maternal plasma concentration (7). However, although the 
dose was 12-250 times higher in animal studies than in hu-
man studies, no teratogenic effect was observed (12). Further, 
in human subjects, no metoclopramide-related congenital 
malformation or fetal toxicity has been reported yet. In the 
Michigan Medicaid Surveillance Study, a major birth defect 
was observed only in 10 (5.2%) out of 992 newborns that were 
exposed to metoclopramide in the first trimester (expected: 
8/992) (9). In the study of Sørensen et al. (13), in which they 
compared 309 newborns with exposure to metoclopramide 
during conception or pregnancy with the control group in-
cluding 13327 cases, no increase was detected in congenital 
malformation (OR: 1.1, 95% CI: 0.60-2.06), low birth weight (OR: 
1.79, 95% CI: 0.83-3.86), or preterm labor risk (OR: 1.02, 95% CI: 
0.62-1.67). Similarly, in a retrospective cohort study examining 
81703 single births, Matok et al. (14) found no increase in the 
risks of congenital malformation, preterm labor, perinatal mor-
tality, low birth weight, and low APGAR score with exposure to 
metoclopramide during the first trimester.
Histamine-2 (H2) Receptor Blockers
H2 receptor blockers are the safest and most widely used drugs 
in pregnant women with heartburn that do not respond to life-
style modifications and antacids. All H2 receptor blockers are in 
FDA pregnancy category of B. Cimetidine and ranitidine have 
been used in pregnancy for about 30 years owing to their high 
safety profiles. On the other hand, specific safety studies have 
been conducted only for ranitidine (5). Although animal stud-
ies have revealed that cimetidine exhibited anti-androgenic 
action and caused reduction in the sizes of testis, prostate, 
and seminal vesicle, no anti-androgenic effect associated with 
H2 receptor blockers was demonstrated in any newborns in 
the human data (15). According to the data of the Michigan 
Medicaid Surveillance Study, in 229101 pregnancies examined 
between 1985 and 1992, major congenital malformation was 
observed in 20 (4.3%) out of 460 newborns that were exposed 
to cimetidine in the first trimester and in 23 (4.5%) out of 560 
newborns that were exposed to ranitidine in the first trimester. 
These data were found to be similar to the results of newborns 
without the exposure to H2 receptor blockers (4.3%) (9). Simi-
larly, in the multi-centered international study of Ruigómez 
et al. (16), it was demonstrated that the use of cimetidine (RR: 
1.2, 95% CI: 0.6-2.3) or ranitidine (RR: 1.4, 95% CI: 0.8-2.4) during 
pregnancy did not cause an increase in the risk of non-genetic 
congenital malformation.
Data on the safety of famotidine and nizatidine are fewer than 
those on the safety of ranitidine and cimetidine. While fetal tox-
icity or teratogenicity associated with famotidine was not re-
ported in animal studies, it was revealed that the rates of abor-
tus, low birth weight, and fetal loss increased when nizatidine 
was used in rabbits at a dose 300 times higher than the dose 
recommended for human subjects (17,18).
In a meta-analysis examining the data of 4 studies on the safety 
of all the H2 receptor blockers in pregnancy (2398 exposure 
to H2 receptor blockers vs. no exposure to 119892 H2 recep-
tor blockers), no increased risk was detected for spontaneous 
abortus (OR: 0.62, 95% CI: 0.36-1.05), preterm labor (OR: 1.17, 
95% CI: 0.94-1.47), or growth retardation according to gesta-
tional age (OR: 0.28, 95% CI: 0.06-1.22) (19).
Proton Pump Inhibitors 
Proton pump inhibitors (PPI) are the most effective drugs used 
in the treatment of reflux symptoms and esophagitis. However, 
the use of PPIs in pregnancy is not as common as H2 receptors, 
and data on the safety of these drugs in pregnancy are more 
restricted.
While omeprazole, rabeprazole, and esomeprazole are FDA cat-
egory-C agents, others are FDA category-B medications. Dose-
related mortality developed in the embryos of pregnant rabbits 
and rats at the doses of omeprazole used in human beings, but 
no teratogenicity was observed (20). Moreover, no increase was 
found in the risk of congenital malformation in a meta-analysis 
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examining 5 studies (a total of 534 births) about the safety of 
omeprazole exposure (RR: 1.05, 95% CI: 0.59-1.85) (21).
In animal studies in which lansoprazole was used at a dose 40 
times higher than that recommended for human subjects, im-
paired fertility or fetal toxicity was not detected (22). In a study 
comparing 62 cases with lansoprazole exposure to a control 
group, while the frequency of congenital anomaly was 3.9% in 
the lansoprazole group, it was 3.8% in the control group (23).
The safety of using rabeprazole, pantoprazole, and esomepra-
zole-which are newer PPIs-in pregnancy was proven in some 
animal experiments (9). In the meta-analysis conducted by Gill 
et al. (24) in 2009, including 6 prospective and retrospective co-
hort studies concerning the safety of omeprazole, pantoprazole, 
and lansoprazole were included. According to the results of this 
meta-analysis, no increase was found in the risk for congenital 
malformation, preterm labor, or spontaneous abortus due to in 
utero exposure to PPIs. Moreover, in another recent study, it was 
confirmed that there was no increase in the risk for congenital 
malformation due to the use of lansoprazole, omeprazole, or pan-
toprazole in the first trimester (OR: 1.06, 95% CI: 0.89-1.33). In addi-
tion, it was also revealed in this study that no increase occurred in 
the risk for preterm labor, perinatal mortality, or low birth weight 
due to exposure to PPIs during the third trimester. 
In the population-based study of Pasternak et al. (25), in which 
the safety of PPIs including omeprazole, lansoprazole, rabepra-
zole, pantoprazole, and esomeprazole was considered, it was 
reported that the risk of birth defect did not increase with the 
use of these agents in the first trimester.
RECOMMENDATIONS
• In the first stage, alginic acid, which is known to be 
safe, can be used (Level of evidence: 3b).
• In pregnant women with preeclampsia, calcium- and 
magnesium-based antacids should be preferred due 
to their effect of lowering the blood pressure (Level of 
evidence: 3b).
• In cases in which antacid therapy is inadequate, rani-
tidine is the preferred H2 receptor blocker (Level of 
evidence: 2a).
• In particular, in pregnant women with reflux accom-
panied by nausea, metoclopramide can be preferred 
(Level of evidence: 2b).
• If no response is obtained to the abovementioned 
therapies, PPIs, except omeprazole, can be given con-
sidering the benefit–harm ratio for mother and fetus 
after the first trimester (Level of evidence: 3a).
SAFETY OF DRUGS IN PATIENTS WITH GERD DURING 
LACTATION PERIOD?
Data on the use of GERD drugs during the lactation period are 
very limited and are restricted to the studies and anecdotes on 
the metabolite level.
The passage of aluminum or magnesium hydroxide into breast 
milk could not be determined. The data on the passage of 
sucralfate into breast milk are insufficient. However, minimal 
absorption of the agent suggests that the passage into breast 
milk will also be at the minimal level (15).
Metoclopramide passes into breast milk. However, no neonatal 
side effect was observed in mothers using up to a dose of 45 
mg/day (7).
Metabolized ranitidine passes into breast milk at a higher rate 
than in plasma, but its effect on infants is unknown. Although 
cimetidine passes into breast milk, its use during the lactation 
period is reported to be safe by the American Academy of Pedi-
atrics. It passes into breast milk at a lesser rate than famotidine, 
ranitidine. In spite of the fact that the passage of nizatidine into 
breast milk is low (0.1%), it was reported to cause growth retar-
dation in animal models (9,26).
There are no data on the passage of omeprazole into breast 
milk. In one case report, satisfactory results were obtained in a 
case with refractory GERD during the lactation period, and no 
neonatal side effect was observed. Although the fact that lan-
soprazole passes into breast milk is unknown, its use is not rec-
ommended. On the other hand, in the only case report on the 
use of pantoprazole, 0.14% of the weight-normalized maternal 
dose was detected in the infant (7.3 μg), but no side effect was 
found in the infant (27,28).
RECOMMENDATIONS
• Data on the safety of medications that can be used 
for patients with GERD during the lactation period are 
not available. Some drugs with minimum systemic 
absorption, such as sucralfate and alginic acid, can be 
used (Level of evidence: 5).
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